News

Under the deal, Blueprint will identify and optimize drug candidates using its kinase-focused drug discovery platform. The company will also conduct all research activities before filing an investigational

As part of the deal, GSK’s existing opiates business including related manufacturing sites in Latrobe (Tasmania) and Port Fairy (Victoria), and its portfolio of opiates products along with

The expansion will include emerging areas of research in the immune response to tumor neo-antigens, truly tumor-specific antigens generated as tumors accumulate genetic mutations. Additionally, new T cell

Lenvima is an orally administered molecular targeted agent that selectively inhibits the activities of an array of different molecules including VEGFR, FGFR, RET, KIT and PDGFR. VEGFR, FGFR

BL-8040, which is designed to treat acute myeloid leukemia, as well as other hematological indications, mobilizes cancer cells from the bone marrow and may therefore sensitize these cells

A total of 70 patients have been enrolled in the trial, which is examining the ability of AQX-1125 to reduce pain in female patients with BPS/IC, a chronic

The randomized, double blind and placebo controlled trial, which will be conducted in several European countries, is designed to assess the safety and effects of a two-week treatment

Manufactured using patented nab technology, Abraxane (paclitaxel formulated as albumin-bound nanoparticles, or nab-paclitaxel) is approved to treat NSCLC patients who are not candidates for potentially curative surgery and/or

Under the deal, GSK has acquired Novartis’s global Vaccines business (excluding influenza vaccines) for $5.25bn. Both the companies have created a new consumer healthcare joint venture in which